World Pharma Innovation Congress USA - list of speakers 

Dr. Robert J. Beall has been with the Cystic Fibrosis Foundation for over 30 years. He began his tenure at the CF Foundation as Executive Vice President for Medical Affairs, and for the past 16 years he has served as President and Chief Executive Officer. Prior to joining the CF Foundation, Dr. Beall was on the medical school faculty of Case...

Dr. Bingham is a member of the Board and co-founder of InnoCentive, Inc. He has been a strong advocate of open innovation and founded InnoCentive, Inc., along with other ventures that create the advantages of open and networked organizational structures, including: YourEncore, Inc., Coalesix, Inc., Maaguzi, Inc., Indigo...

Dr. Bodick is a founder of Flexion Therapeutics, where he has served as Chief Medical Officer for the last four years. Previously, he was the founder and Chief Medical Officer of Chorus, an autonomous early-phase drug development accelerator within Eli Lilly Research Laboratories. Prior to leading Chorus, Dr. Bodick was responsible for...

Bruce Booth is a Partner in the Life Sciences group and joined Atlas Venture in 2005. He focuses on novel biopharmaceutical products, therapeutic platforms and innovative biomedical technologies. Bruce currently serves on the Boards of Atlas portfolio companies Avila, Bicycle, Miragen, Nimbus, OnQity, ProtAffin and Zafgen. He also works or has...

Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery. Dr. Bunin has overseen over $20 million in business transactions. Prior to CDD, Dr. Bunin was an Entrepreneur in Residence with Eli Lilly & Co. Before that he was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, Dr. Bunin led a team that integrated ...

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Board of Abunda Corporation, and is a member of the Boards of...

Henry Chesbrough is Executive Director of the Center for Open Innovation at the Haas School of Business at UC Berkeley. Previously, he was an assistant professor of business administration, and the Class of 1961 Fellow at the Harvard Business School. He holds a Ph.D. in Business Administration from the University of California-Berkeley, an MBA...

Sohini Chowdhury joined the Foundation after spending five years at the World Economic Forum in Geneva, Switzerland. As the Senior Community Manager of the Forum's Technology Pioneers program, she was responsible for annually selecting and integrating innovative biotech, energy and IT technology companies into Forum activities. Ms. Chowdhury also...

Chester “Chip” Davis, Jr. currently serves as Executive Vice President for Advocacy at PhRMA. In this role Davis is responsible for leading and managing PhRMA’s federal, state and international government relations and advocacy efforts. A veteran of the biopharmaceutical research industry, Davis served as Senior Operating Office of PhRMA from...

As Chief Mission Officer, Dr. DeGennaro's current responsibilities include oversight of all LLS mission functions: Public Policy, Patient Services and Research with the goal of effectively deploying resources in pursuit of the LLS mission to cure leukemia, lymphoma and myeloma and improve the quality of life for patients and their families. The...

Author of The New Evolution Diet and Hollywood Economics, the most acclaimed book on the movie business One of the most original thinkers in health who recast diet and fitness in terms of evolution and complexity, Dr. De Vany is called the Patriarch of the growing Paleo movement in diet and exercise (New York Times, London Times). The New...

Tariq Ghayur received a Ph.D in Immunology from McGill University, Montreal, Canada. He did his post-doctoral training at McGill (1986-’88) and Dana Farber Cancer Institute (1988-’90). He joined BASF Pharma (1990), which was acquired by Abbott Laboratories in 2000. He has worked on both small molecule and therapeutic antibody programs. Since 1996 ...

Dr. Corey Goodman is a Founding Partner of venBio – a new life sciences strategic capital company working with Amgen, Baxter, and PPD. With a B.S. from Stanford University and Ph.D. from U.C. Berkeley, he spent 25 years as a biology professor at Stanford and Evan Rauch Chair of neurobiology at U.C. Berkeley, where he was Howard Hughes Medical...

Dr. Goodman became Chief Scientist and Deputy Commissioner for Science and Public Health of the FDA in 2009. He has broad responsibility for and engagement in leadership and coordination of the Agency’s cross-cutting scientific and public health efforts. From 2003-2009, he was Director of FDA’s Center for Biologics Evaluation and Research...

Dr. Handelin is a veteran entrepreneur and molecular medical geneticist who has pioneered the responsible application of genetics to clinical medicine over a 25 year career. In 1987 Dr. Handelin established one of the first commercial DNA testing laboratories at Integrated Genetics (now Genzyme Genetics). After co-founding a gene therapy company...

Christopher Haskell leads Bayer’s U.S. Science Hub, based in the company’s U.S. Innovation Center located at Mission Bay, San Francisco. Charged with expanding Bayer’s collaborations with academic research institutions and life science firms, the Science Hub is part of Bayer’s Global Drug Discovery organization. Since joining Bayer in...

Katherine Holland brings more than thirty years of global leadership, expertise, industry insight and client experience to her current position as IBM’s General Manager, Global Life Sciences Industry. She leads the world wide strategy, solutions development, P&L and client satisfaction for clients in the biotech, pharmaceutical, medical diagnostic ...

Thomas Hughes, PhD has more than 24 years of experience in the biomedical and pharmaceutical research and development. Dr. Hughes is President and CEO of Zafgen, Inc – a biotech company focused on treatment of severe obesity and its related cardiometabolic risk factors, and a member of the Zafgen Board of Directors since 2008. From...

Florian Jehle is a Principal with Catenion and lives in Berlin Florian started his consulting career in 2002 and joined Catenion in 2005. Florian has worked on multiple projects for many pharmaceutical, medical products and diagnostics companies. He has covered topics ranging from strategy development and portfolio management to organizational...

Regis Kelly, PhD, is director of the California Institute for Quantitative Biosciences (QB3). Prior to joining QB3 in 2004, Dr. Kelly served as executive vice-chancellor at UCSF; he oversaw the UCSF research enterprise and was also responsible for construction of the new Mission Bay campus. He is currently chairman of the Bay Area Scientific...

Tom is an experienced change leader in medical and clinical business areas. He has a rich background including hospital and retail pharmacy, international healthcare development in sub-Saharan Africa, and clinical development in the pharmaceutical industry. Bringing medical, business and information together is Tom’s passion and has been the...

Douglas Lowy is the Deputy Director of the National Cancer Institute (NCI) part of The National Institutes of Health, and the chief of the Laboratory of Cellular Oncology in the Center for Cancer Research. Dr. Lowy received his medical degree from New York University School of Medicine and trained in internal medicine at Stanford University and...

Kevin has spent most of the past 29 years either managing research groups or running his own experiments at the bench. He is co-founder and CEO of Assay Depot, which owns and operates a network of online research exchanges that have the potential to dramatically improve how scientific research is done. In 2001, Kevin co-founded Kalypsys, a fully ...

Joseph P. Miletich, M.D, Ph.D. is Senior Vice President, Research and Development at Amgen, Inc. where he created and leads the company’s innovative Translational Sciences organization. This critical part of Amgen’s R&D effort unlocks the promise of early discoveries by demonstrating their potential to alter disease in a beneficial...

Lesa Mitchell is a vice president with the Kauffman Foundation. She has been responsible for the Foundation’s frontier work in understanding the policy levers that influence the advancement of innovation from universities into the commercial market and the new relationships between philanthropy and for profit companies. Under Mitchell’s...

Bernard Munos is the founder of the InnoThink Center for Research in Biomedical Innovation, which was created to translate innovation research into better evidence-based business models for the pharmaceutical industry and its stakeholders. Before that, he was Advisor for corporate strategy at Eli Lilly and Company where he focused on disruptive...

Francois Nader has been president and chief executive officer of NPS Pharmaceuticals, Inc. since March 2008. Dr. Nader joined NPS in June 2006 and served as executive vice president and chief operating officer until March 2008. In that capacity, he was responsible for managing the company’s worldwide research and development, commercial...

Jack D. Newman, Ph.D., co-founded Amyris with over a decade of experience researching bacterial physiology and genetics. In addition to publishing in leading molecular biology and biotechnology journals, Dr. Newman co-authored the groundbreaking work underlying the technology of microbial terpene production. Dr. Newman received his doctorate from...

Jess Rabourn, CFA is a trained institutional investor and has a quantitative finance background that includes work at Morgan Stanley, Thomson/Reuters, and Allianz Global Investors (AGI). He has portfolio management experience in equity and fixed income, and he covered macro-economic and volatility arbitrage strategies at AGI’s hedge fund...

Mike has worked in global pharma for over twenty years, and is a recognized industry leader, named as The Change Maker in the PharmaVoice 100 Most Inspiring Individuals in Healthcare in 2011. Since founding product design company IDEA Pharma, Mike has led path-to-medicine strategy for over 60 pharmaceutical brands, including over half of the 50...

Ellis Rubinstein is an innovator and change agent. As a science journalist, his work merited 3 National Magazine Awards, the Pulitzer Prizes of the American periodicals industry. As an editor at Newsweek, the journal Science, Rubinstein increased impact through landmark articles and special issues. At Science, he pioneered in Web publishing. As...

Ted is Vice President and Global Head of External Innovation & Business Models for CREATe within Johnson & Johnson’s Pharmaceuticals Group. In this role he is responsible for building and managing a portfolio of external R&D collaborations on products and technologies, as well as establishing creative business and funding models to advance...

Dr. Warmke is currently Senior Vice President, Daiichi Sankyo Group and leads the External Scientific Affairs group responsible for identification and evaluation of Product Licensing and Research and Development collaboration opportunities, and he also heads the co-development partner Alliance Management function. Dr. Warmke began his career in...

John Wilbanks works on open content, open data, and open innovation systems in the life sciences and sustainability. He has worked at Creative Commons, the Berkman Center for Internet & Society at Harvard University, MIT’s Computer Science and Artificial Intelligence Laboratory, the World Wide Web Consortium, and the US House of...

Timothy M. Willson is Director of Chemical Biology at GlaxoSmithKline (GSK) in Research Triangle Park NC, where he leads a multidisciplinary team in the identification of innovative targets for drug discovery. Current areas of focus include chemical regulators of epigenetic signaling, small molecule regulation of the circadian clock, inhibition of ...